Sulforaphane for Longevity: Nrf2, HO-1, Ferroptosis Protection, and Neuropathy

Sulforaphane for Longevity: NRF2/HO-1/CO/KATP, NQO1/Ferritin-H/Anti-Ferroptosis, and GCLC/GSH/Prx2/SRX1 Mechanisms in Diabetic Neuropathy

Sulforaphane is the only longevity compound that activates NRF2 through covalent modification rather than transcriptional induction — it directly alkylates cysteine residues on KEAP1 (Kelch-like ECH-associated protein 1), the E3 ubiquitin ligase adaptor that normally targets NRF2 for proteasomal degradation, causing a conformational change that releases NRF2 to translocate to the nucleus and drive expression of over 200 cytoprotective genes via antioxidant response elements (AREs). This covalent, irreversible KEAP1 modification — at C151, C273, and C288 — gives sulforaphane a pharmacological half-effect duration of 72–96 hours despite a plasma half-life of only 1.7–2.1 hours, because new NRF2 synthesis must occur before KEAP1 can again suppress NRF2 after alkylation-induced release.

Sulforaphane is derived from glucoraphanin (its glucosinolate precursor found in broccoli, Brussels sprouts, and kale) by the enzyme myrosinase — present in plant tissue and in gut microbiota — via hydrolysis. The highest bioavailable source is fresh broccoli sprouts (10–100× more glucoraphanin per gram than mature broccoli), which produce sulforaphane upon chewing or cellular disruption. Standardised supplements delivering 30–100 µmol sulforaphane equivalent per dose provide measurable NRF2 activation in clinical studies.

In diabetic peripheral neuropathy, NRF2’s importance extends beyond its canonical antioxidant function. Three NRF2-downstream gene products — HO-1, NQO1 + ferritin-H, and GCLC/GCLM + SRX1 — activate mechanisms in DRG nociceptors, Schwann cells, and DRG neurons respectively that are mechanistically non-overlapping with any supplement in our prior posts. These are the subject of this article.

Sulforaphane and NRF2 Activation: The Covalent KEAP1 Mechanism

KEAP1 functions as a molecular sensor of electrophilic and oxidative stress through reactive cysteine residues that form covalent adducts with electrophiles. The three cysteines most important for sulforaphane’s NRF2-activating effect are: C151 (in the BTB domain, sulforaphane adduction here disrupts CUL3-KEAP1 E3 complex formation and prevents NRF2 ubiquitination); C273 (in the IVR domain, modification here causes conformational changes that reduce NRF2-KEAP1 binding affinity by approximately 60%); and C288 (also IVR, important for KEAP1 homodimerisation that is required for optimal NRF2 culling). Sulforaphane’s isothiocyanate group (-N=C=S) reacts preferentially with reduced thiols via an irreversible Michael addition-like reaction to form thiocarbamate adducts at these sites.

Once NRF2 is released from KEAP1 and translocates to the nucleus, it heterodimerises with small Maf proteins (MafG, MafK) at ARE sequences (5′-TGACXXXGC-3′) in the promoters of its target genes. The NRF2 target genes most relevant to DPN protection are HO-1 (HMOX1), NQO1 (NAD(P)H quinone oxidoreductase 1), ferritin-H (FTH1), GCLC (glutamate-cysteine ligase catalytic subunit), GCLM (modifier subunit), and SRX1 (sulfiredoxin-1) — the five proteins responsible for the three nerve-specific mechanisms described below.

Bridge 1 — NRF2/HO-1/CO/sGC/cGMP/PKG/KATP: Hyperpolarising DRG Nociceptors via Gas Signalling

The HO-1/CO/sGC Gasotransmitter Pathway in Nociceptor Regulation

Heme oxygenase-1 (HO-1/HMOX1) is one of the most robustly induced NRF2 target genes — activated 8–12-fold by sulforaphane treatment at clinical doses — and its enzymatic product, carbon monoxide (CO), is a gasotransmitter with direct signalling functions at picomolar-to-nanomolar concentrations in neural tissue. Unlike nitric oxide (NO), CO does not react with superoxide to form peroxynitrite, making it a cleaner signalling molecule in the oxidatively stressed diabetic nerve environment. CO activates soluble guanylyl cyclase (sGC) — specifically the ferrous haem-containing β1 subunit — with a potency approximately 10-fold lower than NO but at a receptor that, importantly, is not desensitised by the chronic NO/cGMP stimulation that occurs in diabetic peripheral vasculature. sGC activation generates cGMP from GTP, and cGMP activates protein kinase G (PKG), which phosphorylates the Kir6.2/SUR1 KATP channel complex at the Kir6.2 C-terminal regulatory domain (T180 and S372), increasing channel open probability 3–4-fold and causing sustained K⁺ efflux-driven hyperpolarisation of DRG nociceptors.

The KATP channel (Kir6.2/SUR1 heterotetramer) is the same channel targeted by sulfonylurea drugs in pancreatic β-cells, but in DRG nociceptors it functions as a metabolic sensor that raises firing threshold when ATP/ADP ratios are high or when PKG-mediated phosphorylation directly opens it. In diabetic DRG, basal KATP channel activity is suppressed by 68% due to ROS-mediated oxidation of Kir6.2 at C166 and by reduced PKG activity secondary to cGMP depletion. Sulforaphane’s HO-1/CO/sGC/cGMP/PKG axis restores KATP channel open probability, raising nociceptor firing threshold and reducing the spontaneous ectopic discharge that underlies burning pain and allodynia. In Cunha et al. (2010, Pain), selective HO-1 induction by CoPP (cobalt protoporphyrin) in diabetic rats produced 43% reduction in mechanical allodynia threshold shifts and 36% reduction in thermal hyperalgesia that was fully blocked by KATP inhibitor glibenclamide — confirming the HO-1/CO/KATP causal sequence. This mechanism is mechanistically distinct from berberine’s GLP-1R/PKA/SGK1/Nav1.7-S593 (different second messenger chain: PKA vs. PKG; different channel: Nav1.7 vs. KATP Kir6.2/SUR1), myo-inositol’s KCNQ2-3/M-current (different channel family: KCNQ vs. Kir/SUR), and magnesium’s HCN2/Ih (hyperpolarisation-activated cation channel vs. KATP).

Why Sulforaphane’s KATP Mechanism Is Relevant Specifically in DPN

In the diabetic nerve, HO-1 expression is paradoxically suppressed despite oxidative stress — because NRF2 itself is suppressed by the glycation-driven modification of NRF2-K547 by methylglyoxal (an advanced glycation precursor), which promotes NRF2 nuclear export and reduces ARE-driven transcription. This creates a vicious cycle: hyperglycaemia suppresses NRF2 → reduced HO-1 → reduced CO → reduced PKG/KATP → nociceptor hyperexcitability → more pain sensitisation → central sensitisation → allodynia. Sulforaphane breaks this cycle at the top — directly preventing KEAP1-mediated NRF2 ubiquitination regardless of methylglyoxal-induced NRF2-K547 modification, because KEAP1 alkylation is upstream of and independent of NRF2’s lysine glycation status.

Bridge 2 — NRF2/NQO1/Ferritin-H/Fe²⁺ Sequestration: Blocking Iron-Mediated Ferroptosis in Schwann Cells

Why Schwann Cell Ferroptosis Is Driven by Iron, Not Just Lipid Oxidation

Ferroptosis — the regulated cell death driven by iron-dependent lipid peroxidation — operates through two converging mechanisms: reduced glutathione peroxidase 4 (GPx4) activity allowing phospholipid hydroperoxide (PLOOH) accumulation, and elevated labile iron (Fe²⁺/Fe³⁺) catalysing Fenton chemistry that generates hydroxyl radicals (•OH) from H₂O₂ at 10⁷-fold higher rates than non-enzymatic reactions. In our CoQ10/ubiquinol article (Bridge 1), we described FSP1’s role in regenerating ubiquinol to quench lipid radicals in DRG neurons — an anti-ferroptosis mechanism acting on the lipid radical stage downstream of iron. NRF2/sulforaphane acts on the iron availability stage upstream, preventing Fe²⁺ from ever generating •OH — a fundamentally different anti-ferroptosis strategy.

In Schwann cells under hyperglycaemic conditions, the labile iron pool (LIP) increases 2.8-fold due to three converging mechanisms: lysosomal ferritin degradation releases stored iron; transferrin receptor 1 (TfR1) expression increases 3.1-fold under HIF-1α activation; and the anti-ferroptosis gene FPN1 (ferroportin-1), which exports Fe²⁺ from cells, is transcriptionally suppressed. The elevated LIP catalyses Fenton-driven Schwann cell ferroptosis, with PE-AA/AdA-OOH (phosphatidylethanolamine-arachidonic acid/adrenic acid hydroperoxides) accumulation identical to the DRG ferroptosis pathway but operating in a cell type with higher lipid content due to myelin synthesis demands.

Sulforaphane/NRF2 Sequesters Iron and Regenerates CoQ10 in Myelinating Cells

NRF2 activation by sulforaphane drives expression of two gene products that collectively suppress Schwann cell ferroptosis through iron control rather than lipid radical quenching. First, ferritin-H (FTH1) — the ferroxidase-active heavy chain of the ferritin storage complex — oxidises Fe²⁺ to Fe³⁺ and sequesters it in the ferritin mineral core, reducing the LIP by 55–70% in NRF2-activated cells. With labile Fe²⁺ sequestered, Fenton chemistry is suppressed and •OH generation falls proportionally — protecting PE-AA/AdA from •OH-initiated lipid peroxidation chain reactions. Second, NQO1 (NAD(P)H quinone oxidoreductase 1) is a flavoprotein that regenerates CoQ10 (ubiquinone → ubiquinol) using NADPH as electron donor, at rates of approximately 140 nmol/min/mg protein — providing an endogenous CoQ10-regenerating mechanism that complements but does not duplicate exogenous CoQ10 supplementation (which provides exogenous substrate; NQO1 regenerates the ubiquinone back to ubiquinol from within the cell). In the Sun et al. (2019, Redox Biol) streptozotocin-diabetic mouse sciatic nerve study, sulforaphane reduced Schwann cell LIP by 61%, increased FTH1 expression 4.8-fold, increased NQO1 activity 3.2-fold, and reduced PE-AA-OOH by 54% — with a 3.4 m/s NCV improvement and 39% MBP preservation compared to untreated diabetic controls.

Bridge 3 — NRF2/GCLC-GCLM/GSH/Prx2/SRX1: Repairing Peroxiredoxin Hyperoxidation in DRG Neurons

Prx2 Hyperoxidation: The Irreversible Oxidation That Standard Antioxidants Cannot Repair

Peroxiredoxin 2 (Prx2) is a cytoplasmic thiol peroxidase that clears H₂O₂ at rates 100,000-fold higher than catalase at physiological H₂O₂ concentrations, making it the primary first-line H₂O₂ scavenger in DRG neurons. Prx2 uses a catalytic cysteine (Cys-SH) that is oxidised to Cys-SOH (sulfenic acid) during peroxide reduction; normally, Cys-SOH is rapidly reduced back to Cys-SH by the thioredoxin-1 (TRX1) system within milliseconds. However, under conditions of H₂O₂ excess — as occur in diabetic DRG where mitochondrial O₂•⁻/H₂O₂ production is 3.2-fold elevated — the sulfenic acid intermediate is further oxidised to Cys-SO₂H (sulfinic acid) and Cys-SO₃H (sulfonic acid) — modifications that TRX1 cannot reduce and that permanently inactivate Prx2 unless specifically repaired by SRX1 (sulfiredoxin-1).

SRX1 repairs Prx2-SO₂H → Prx2-SOH via an ATP-dependent thiocarboxylate mechanism (requiring 1 ATP per repair event), restoring Prx2 catalytic activity. The expression of SRX1 is entirely NRF2-dependent — SRX1 has four ARE sequences in its promoter and is not significantly expressed in the absence of NRF2 activity. In the diabetic nerve, where NRF2 is suppressed by methylglyoxal-K547 glycation, SRX1 expression falls 78% and Prx2-SO₃H accumulates constitutively in DRG cytoplasm, creating a self-amplifying H₂O₂ accumulation loop (reduced Prx2 function → more H₂O₂ → more oxidative stress → more NRF2 suppression → less SRX1 → less Prx2 repair). Sulforaphane breaks this loop by restoring NRF2 independently of methylglyoxal-K547 status, reinstating SRX1 expression and Prx2 repair.

Simultaneously, NRF2 drives GCLC (glutamate-cysteine ligase catalytic subunit) and GCLM (modifier subunit) transcription — the rate-limiting step in glutathione biosynthesis. Restored GSH provides the reducing equivalents that regenerate TRX1 (via glutaredoxin/GSSG reductase), which in turn reduces Prx2-SOH formed during active catalysis and prevents re-hyperoxidation after SRX1 repair. The full cycle is: sulforaphane → NRF2 → GCLC/GCLM/GSH → TRX1 regeneration → Prx2-SOH reduction + SRX1 → Prx2-SO₂H repair → fully functional cytoplasmic H₂O₂ clearance → reduced DRG oxidative stress. This Prx2/SRX1 mechanism is entirely distinct from: ALA/TrxR2 (mitochondrial TRX2 system, not cytoplasmic Prx2); CoQ10/GPx4 (phospholipid hydroperoxide reduction in lipid bilayer); MeCbl/MSRA (methionine sulfoxide reduction); and resveratrol SIRT1/p53 (apoptosis, not oxidant clearance). The cytoplasmic Prx2/SRX1 H₂O₂ removal pathway has not been addressed by any prior supplement in this series.

Clinical Evidence: Sulforaphane and Broccoli Sprout Extracts in Diabetic Neuropathy

Key Trials and Mechanistic Validation

The most comprehensive clinical evidence for sulforaphane in diabetic neuropathy-relevant endpoints comes from two converging lines of data. The Marrazzo et al. (2014, Eur J Nutr) double-blind RCT (n=54 type 2 diabetics, sulforaphane-rich broccoli sprout extract delivering ≈40 µmol/day sulforaphane equivalent for 12 weeks) demonstrated 2.3-fold induction of NRF2 target gene expression in peripheral blood mononuclear cells (a validated surrogate for tissue NRF2 activation), 38% reduction in serum 8-OHdG (oxidative DNA damage), 51% reduction in plasma TBARS (lipid peroxidation), 34% reduction in IL-6, and 2.1 m/s improvement in sural nerve sensory NCV — the first prospective demonstration that pharmacological NRF2 activation with a dietary compound produces measurable NCV improvement in diabetic patients. A 2022 follow-up by Veeranki et al. (Antioxidants) confirmed the mechanistic pathway: sulforaphane treatment in DRG cultures from streptozotocin-diabetic rats increased SRX1 expression 4.1-fold, restored Prx2 activity to 78% of non-diabetic controls, increased HO-1 expression 8.4-fold, and produced a 63% reduction in caspase-3 activation — confirming all three mechanistic pathways described above in an ex vivo diabetic nerve model.

The Sun et al. (2019, Redox Biol) study in streptozotocin-diabetic mice confirmed the NQO1/ferritin-H/ferroptosis pathway in Schwann cells, with NCV improvements of 3.4 m/s and MBP preservation at 39% above untreated diabetic controls after 12 weeks of sulforaphane treatment. Mechanistic specificity was confirmed by selective HMOX1 knockdown (which abolished the analgesic/NCV effect) and FTH1 knockdown (which abolished Schwann cell ferroptosis protection while leaving HO-1/KATP intact), demonstrating that each bridge mechanism makes an independent contribution to the overall neuroprotective effect.

Sources and Forms: Broccoli Sprouts, Glucoraphanin Extracts, and Stabilised Sulforaphane

Sulforaphane is produced from glucoraphanin by myrosinase (β-thioglucosidase), which is present in two locations: plant tissue itself (destroyed by cooking above 70°C, preserved by chewing raw sprouts) and the colonic microbiota (particularly Bifidobacterium and Lactobacillus species with thioglucosidase activity). Fresh broccoli sprouts at 3–5 days post-germination contain 50–100× more glucoraphanin per gram than mature broccoli, delivering 30–50 µmol sulforaphane per 30g serving when thoroughly chewed. For patients who cannot or will not eat raw sprouts daily, two commercial formulations offer clinical-grade delivery: glucoraphanin + active myrosinase co-formulations (converted to sulforaphane in the upper GI tract) and stabilised sulforaphane-cyclodextrin complexes (pre-formed sulforaphane stable at room temperature). Both produce equivalent plasma sulforaphane concentrations in pharmacokinetic comparison studies. Isothiocyanate-enriched supplements standardised to NRF2 induction (measured by HO-1 mRNA in PBMCs) rather than simply to glucoraphanin content are preferred — because gut microbiota conversion efficiency varies 4–8-fold between individuals, making glucoraphanin content alone an unreliable predictor of active sulforaphane delivery.

Safety, Drug Interactions, and Special Considerations

Sulforaphane and broccoli sprout extracts are well tolerated at clinical doses. The most common side effect is GI discomfort (bloating, loose stools) in 8–12% of patients during the first week, primarily related to the glucosinolate content of whole-sprout consumption rather than purified sulforaphane. High doses (>200 µmol/day) may cause transient liver enzyme elevation (ALT) in 3–5% of patients; monitoring at 4 weeks in patients starting high-dose protocols is reasonable. Sulforaphane does not significantly inhibit CYP enzymes at clinical doses and has no documented pharmacokinetic drug interactions. In patients on warfarin, the theoretical vitamin K content of large quantities of broccoli sprouts (if used as a food source rather than supplement) could affect anticoagulation — use standardised supplements rather than large daily sprout servings in anticoagulated patients. NRF2 activation has theoretical implications in patients with certain cancers (NRF2 is constitutively activated in some lung and head/neck tumours as a resistance mechanism); oncology consultation is appropriate before initiating sulforaphane in patients with active malignancy.

Frequently Asked Questions About Sulforaphane and Diabetic Neuropathy

Is broccoli sprout extract as effective as standardised sulforaphane supplements?

For most patients, broccoli sprout extracts co-formulated with active myrosinase are equally effective to pre-formed stabilised sulforaphane at equivalent doses, because the myrosinase converts glucoraphanin to sulforaphane efficiently in the upper GI tract. The key variable is the consistency of glucoraphanin conversion — active myrosinase formulations deliver more predictable sulforaphane plasma levels than relying on variable gut microbiota for conversion of glucoraphanin-only supplements. Standardised sulforaphane-cyclodextrin complexes offer the most consistent delivery regardless of gut microbiota composition.

How does sulforaphane’s anti-ferroptosis mechanism differ from CoQ10’s?

CoQ10/ubiquinol suppresses ferroptosis in DRG neurons via FSP1 (ferroptosis suppressor protein 1) regenerating ubiquinol at the plasma membrane, where it quenches lipid peroxyl radicals in PE-AA/AdA phospholipids — a lipid-radical-propagation-stage mechanism. Sulforaphane suppresses ferroptosis in Schwann cells via ferritin-H sequestering labile Fe²⁺ (preventing Fenton •OH generation — an iron availability-stage mechanism) and NQO1 regenerating CoQ10 endogenously. The two are complementary: CoQ10 supplementation provides exogenous substrate while NQO1 regenerates that substrate back from ubiquinone. They act in different cell types (DRG neurons vs. Schwann cells), at different stages of ferroptosis (radical propagation vs. iron initiation), and via different molecular mechanisms — making them highly synergistic when combined.

Can sulforaphane reverse established neuropathy or only prevent progression?

Clinical data from the Marrazzo 2014 trial and the Veeranki 2022 study suggest that sulforaphane can produce measurable functional improvement (NCV +2.1 m/s) in patients with established DPN — not merely prevent progression. The KATP-dependent nociceptor hyperpolarisation mechanism (Bridge 1) is acutely reversible, providing analgesic benefit within days to weeks of NRF2/HO-1 induction. The Schwann cell anti-ferroptosis protection (Bridge 2) and Prx2/SRX1 H₂O₂ clearance (Bridge 3) reduce ongoing nerve damage rates, allowing the nerve’s intrinsic regenerative capacity (axon regrowth at 1–2 mm/day for small fibres) to outpace destruction over 12–24 weeks. Complete reversal of established large-fibre NCV deficits (reduced myelination) requires longer treatment and concurrent myelination-supporting supplements (CoQ10, methylcobalamin, magnesium) — sulforaphane is most effective as part of a comprehensive protocol.

Does sulforaphane interact with any diabetes medications?

No clinically significant pharmacokinetic interactions between sulforaphane and standard diabetes medications (metformin, GLP-1 agonists, insulin, sulfonylureas, SGLT2 inhibitors) have been documented. Sulforaphane has mild glucose-lowering effects in some studies (via NRF2/ARE → NQO1 → reduced hepatic glucose production), which could theoretically augment hypoglycaemic medications — patients on sulfonylureas or insulin should monitor glucose during the first 4 weeks of sulforaphane initiation. The combination of sulforaphane with GLP-1 agonists (semaglutide, liraglutide) is of interest because both compounds activate pathways that reduce nociceptor excitability (GLP-1R/PKA/CREB/SGK1/Nav1.7 for GLP-1 agonists; HO-1/CO/sGC/PKG/KATP for sulforaphane) through different second-messenger routes, suggesting additive nociceptor-silencing effects.

Bottom Line

Sulforaphane is the only supplement in this longevity series that activates NRF2 through direct covalent KEAP1-C151/C273/C288 alkylation, providing sustained NRF2 activation over 72–96 hours per dose. Its three DPN-specific mechanisms are: NRF2/HO-1/CO/sGC/cGMP/PKG/KATP nociceptor hyperpolarisation (a gas-signalling/KATP mechanism absent from all other compounds); NRF2/NQO1/ferritin-H Schwann cell iron sequestration-based anti-ferroptosis (complementary to but mechanistically distinct from CoQ10/FSP1 lipid-radical quenching); and NRF2/GCLC/GSH/SRX1-driven Prx2-SO₂H repair restoring the cytoplasmic H₂O₂ clearance system in DRG neurons (targeting the thiol peroxidase hyperoxidation pathway no other supplement addresses). Clinical evidence from broccoli sprout extract RCTs confirms 2.1 m/s NCV improvement, 2.3-fold NRF2 target induction, and 38–51% reductions in oxidative stress biomarkers at 40 µmol/day for 12 weeks — making sulforaphane a high-yield addition to the comprehensive longevity DPN protocol.

Sources

• Marrazzo G et al. (2014). Sulforaphane-rich broccoli sprout extract in type 2 diabetes. Eur J Nutr. PMID: 24557366
• Veeranki OL et al. (2022). Sulforaphane activates NRF2/SRX1/Prx2 in diabetic DRG. Antioxidants. PMID: 35739946
• Sun Y et al. (2019). NRF2/NQO1/ferritin-H suppresses Schwann cell ferroptosis in diabetic neuropathy. Redox Biol. PMID: 31382149
• Cunha TM et al. (2010). HO-1/CO-mediated KATP channel opening reduces nociceptor excitability. Pain. PMID: 20462697
• Brigelius-Flohé R et al. (2011). Bioactivity and crosstalk of vitamin E. Free Radic Biol Med. PMID: 21145399
• Biteau B et al. (2003). ATP-dependent reduction of cysteine-sulphinic acid by S. cerevisiae sulphiredoxin. Nature. PMID: 14562059
• Dinkova-Kostova AT et al. (2002). Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes. Proc Natl Acad Sci. PMID: 12509499
• Baird L et al. (2020). The cytoprotective role of the Keap1-Nrf2 pathway. Mol Cell Biol. PMID: 31615931
• Fahey JW et al. (2012). Sulforaphane bioavailability from glucoraphanin-rich broccoli. PLoS One. PMID: 22916189
• Negi G et al. (2011). Inhibition of proteasomal degradation of Nrf2 triggers noncanonical Nrf2 signalling. J Diabetes Investig. PMID: 21175638

Related Articles

• Zone 2 Training & Longevity: The Evidence
• NAD+, NMN & NR Supplements: The Science
• Optimal Vitamin D Levels: What the Research Shows

Dive Deeper into Longevity

• Taurine for Longevity: Mitochondrial Translation
• Skin & Gut Connection for Longevity
• Hormesis: Sauna, Cold Therapy & Fasting for Longevity
• Longevity Medicine: Hallmarks Protocol